ArticleBMC ophthalmology2026
OCT-based morphological prognostic factors for structural improvement after anti-VEGF therapy in wet age-related macular degeneration.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the relationship between baseline optical coherence tomography (OCT) features of wet age-related macular degeneration (wAMD) and prognosis, and evaluate anti-VEGF treatment effects under varying baseline OCT conditions.
methodsThis retrospective study included patients diagnosed with wAMD who underwent monthly anti-VEGF therapy for 1–3 months. Baseline, one-month, and three-month OCTs recorded morphological features. Treatment effectiveness was defined as central retinal thickness (CRT) reduction ≥ 25%, or absence of subretinal fluid (SRF) and intraretinal fluids (IRF) post-treatment.
resultsData from 251 eyes were analyzed. After one injection, effective responders had smaller baseline lesion sizes (11.01 ± 9.93 vs. 12.53 ± 8.80, P = 0.046), lower PED height (124.10 ± 232.55 vs. 216.06 ± 248.66, P < 0.001), and larger baseline IRF (86.52 ± 154.74 vs. 31.26 ± 81.14, P = 0.002) compared to non-responders. After three injections, effective responders continued to show larger baseline IRF (65.94 ± 135.20 vs. 20.28 ± 61.93, P = 0.015). Multivariate analysis indicated greater CRT reductions at one and three months were associated with larger baseline CRT (P < 0.001), larger baseline IRF (P < 0.001 and P = 0.012), and absence of retinal hemorrhage (P = 0.003).
conclusionsBaseline OCT features significantly influence treatment responsiveness in wAMD. Tailoring anti-VEGF regimens based on these features may improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.